Future Microbiol. 2014;9(10):1195-1208. 0 Asymptomatic Never diagnosed to have ABPA in the past, presentation with controlled asthma (according to GINA guidelines) and meeting the diagnostic criteria ...

The primary treatment goals of ABPA include controlling symptoms of asthma or cystic fibrosis, preventing and/or treating pulmonary exacerbation, decreasing pulmonary inflammation, and reducing the ...

ABPA is only 1 form of Aspergillus-related lung disease. Other conditions include aspergilloma, invasive or semi-invasive aspergillosis and bronchocentric granulomatosis. The latter, while ...

Please provide your email address to receive an email when new articles are posted on . This case study indicates reduced steroid use with biologic treatment. Treatment reduced IgE levels and ...

The Food and Drug Administration has granted Fast Track designation to PUR1900 (Pulmazole; Pulmatrix) for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. The ...

Allergic bronchopulmonary aspergillosis (ABPA) is an immunologically mediated lung disorder predominantly triggered by chronic airway exposure to Aspergillus fumigatus. Frequently encountered in ...

LEXINGTON, Mass., Feb. 6, 2023 /PRNewswire/ -- Pulmatrix, Inc. (PULM) (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease ...

Aspergillosis is a condition caused by Aspergillus, an infectious mold. Aspergillus is a type of fungus found abundantly around us (indoors as well as outdoors). In individuals with healthy immune ...

Sinus aspergillosis is a fungal infection that affects the sinuses. People with weakened immune systems and respiratory conditions are more likely to develop this condition. Aspergillus is a mold that ...

Aspergillosis is a disease caused by a filamentous fungi, Aspergillus. The mold is present practically everywhere including trees, grain crops, and soil (outdoors); bedding mattresses, cushions, and ...